<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04747587</url>
  </required_header>
  <id_info>
    <org_study_id>NIMAO/2020-1/JF-01</org_study_id>
    <nct_id>NCT04747587</nct_id>
  </id_info>
  <brief_title>Non-use After Stroke: Influence of Applied Force and Precision When Reaching With the Paretic Upper Limb</brief_title>
  <acronym>OPTISTROKE</acronym>
  <official_title>Non-use après Accident Vasculaire cérébral : Influence de la Force et de la précision du Geste à Fournir Lors Des Mouvements du Membre supérieur parétique</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire de Nīmes</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire de Nīmes</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      After a stroke, 80% of patients have an upper limb deficit, limiting activity. Some develop a&#xD;
      non-use: they can, but do not, use their paretic limb. Non-use is a general phenomenon&#xD;
      applied to all situations where the patient applies unnecessary compensation. Several&#xD;
      rehabilitation techniques are effective to counter non-use, but there is insufficient&#xD;
      knowledge to choose the most suitable technique. Optimal control theory could help guide&#xD;
      these choices. It assumes that the chosen coordination satisfies the constraints of the task&#xD;
      (force, amplitude, tolerance) while reducing the cost of the movement. This study will assess&#xD;
      non-use by anticipating the sensitivity to the constraints of force and precision deduced&#xD;
      from the logic of optimal control. The study authors expect to observe a weakness effect: in&#xD;
      a reaching task (i.e. when the person has to touch an object placed in front of them),&#xD;
      lightening the paretic arm makes it possible to reduce non-use, and a precision effect: in a&#xD;
      reaching task, non-use increases with the required spatial precision.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 11, 2021</start_date>
  <completion_date type="Anticipated">September 2022</completion_date>
  <primary_completion_date type="Anticipated">September 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluate the modifications of the proximal non-use after stroke on the paretic side according to the extent of force constraint</measure>
    <time_frame>Inclusion</time_frame>
    <description>Proximal Arm Non Use (PANU) score (%): A significant PANU (&gt; 7.5%) indicates non-use</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evaluate the modifications of the proximal non-use after stroke on the paretic side according to the precision required</measure>
    <time_frame>Inclusion</time_frame>
    <description>PANU score (%): Physiological non-use considered as a decrease in PANU due to to the increase in the size of the target; A psychological non-use considered as absence of decrease in PANU, regardless of the condition</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate the modifications of the proximal non-use in the control subjects according to the constraints of force or precision</measure>
    <time_frame>Inclusion</time_frame>
    <description>PANU score (%) of force and precision</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate the level of neuromuscular activation during reaching</measure>
    <time_frame>Inclusion</time_frame>
    <description>% Voluntary Maximum Contraction (VMC) of anterior and intermediate part of the deltoid, biceps brachii and pectoralis major</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Model the constraints and costs explaining non-use patient by patient, to distinguish between physiological and psycho-behavioral non-use</measure>
    <time_frame>Inclusion</time_frame>
    <description>Weight-over-force ratio of the arm (Ratio between 0 &amp; + ∞)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time since stroke (acute, subacute or chronic phase)</measure>
    <time_frame>Inclusion</time_frame>
    <description>months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intensity of arm deficit</measure>
    <time_frame>Inclusion</time_frame>
    <description>Fugl-Meyer Upper Extremity score ) (score between 0 and 66)</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">44</enrollment>
  <condition>Stroke</condition>
  <arm_group>
    <arm_group_label>Patients with stroke</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Controls</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Reaching Session</intervention_name>
    <description>Two x 45 minutes sessions of reaching tasks. Patients in the stroke group will perform the task with the paretic arm using a weight reduction system, allowing movement in the horizontal plane.&#xD;
Subjects in the control group will perform the task with the randomly selected arm weighted at 80% of their maximum voluntary shoulder torque</description>
    <arm_group_label>Controls</arm_group_label>
    <arm_group_label>Patients with stroke</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        The target population corresponds to hemiparetic patients after stroke. The control&#xD;
        population corresponds to subjects without neurological disorder. The two groups will be&#xD;
        matched on age (18-44, 45-64, 65-79, +80) and sex.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Inclusion criteria specific to the stroke group:&#xD;
&#xD;
          -  Patient having had a 1st stroke&#xD;
&#xD;
          -  Patient whose stroke occurred more than a month ago.&#xD;
&#xD;
          -  Patient having had a supratentorial stroke&#xD;
&#xD;
          -  Patient able to touch the opposite knee with the paretic arm&#xD;
&#xD;
        Inclusion criteria specific to the control group:&#xD;
&#xD;
          -  Subject who has never had a stroke&#xD;
&#xD;
          -  Subject without motor or orthopedic impairment of the upper limbs and in particular of&#xD;
             the shoulder&#xD;
&#xD;
          -  Subjects recruited from the families of patients or hospital professionals&#xD;
&#xD;
        General inclusion criteria:&#xD;
&#xD;
          -  Subject who has given free and informed consent.&#xD;
&#xD;
          -  Subject who signed the consent form.&#xD;
&#xD;
          -  Subject affiliated or beneficiary of a health insurance plan.&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          -  Pregnant, parturient or breastfeeding subject.&#xD;
&#xD;
          -  The subject is participating in a category 1 interventional study, or is in a period&#xD;
             of exclusion determined by a previous study&#xD;
&#xD;
          -  The subject refuses to sign the consent&#xD;
&#xD;
          -  It is impossible to give the subject informed information&#xD;
&#xD;
          -  The patient is under safeguard of justice or state guardianship&#xD;
&#xD;
          -  Patient with cognitive disorders incompatible with a good understanding of the use of&#xD;
             the device&#xD;
&#xD;
          -  Patient with other neurological or osteoarticular history that may limit the&#xD;
             performance of the task - criterion left to the deiscretion of the investigator&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jérôme Froger</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre Hospitalier Universitaire de Nīmes</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jérôme Froger</last_name>
    <phone>04.66.02.25.31</phone>
    <email>Jerome.froger@chu-nimes.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>CHU de Montpellier</name>
      <address>
        <city>Montpellier</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Isabelle Laffont</last_name>
      <phone>04 67 33 23 46</phone>
      <email>i-laffont@chu-montpellier.fr</email>
    </contact>
    <investigator>
      <last_name>Isabelle Laffont</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Denis Mottet</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Germain Faity</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Nîmes</name>
      <address>
        <city>Nîmes</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anissa Megzari</last_name>
      <phone>04.66.68.42.36</phone>
      <email>drc@chu-nimes.fr</email>
    </contact>
    <investigator>
      <last_name>Jérôme Froger</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>February 5, 2021</study_first_submitted>
  <study_first_submitted_qc>February 5, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 10, 2021</study_first_posted>
  <last_update_submitted>June 14, 2021</last_update_submitted>
  <last_update_submitted_qc>June 14, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Non-use</keyword>
  <keyword>Compensation</keyword>
  <keyword>Weakness</keyword>
  <keyword>Optimal control</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stroke</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Anonymised raw datasets and code used for the analysis will be available on reasonable request.</ipd_description>
    <ipd_info_type>Analytic Code</ipd_info_type>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

